- Open Access
IMP/GTP balance modulates cytoophidium assembly and IMPDH activity
- Gerson Dierley Keppeke†1,
- Chia Chun Chang†1, 2,
- Min Peng2,
- Li-Yu Chen1,
- Wei-Cheng Lin3,
- Li-Mei Pai3, 4, 5,
- Luis Eduardo Coelho Andrade6,
- Li-Ying Sung2, 7Email author and
- Ji-Long Liu1, 8Email authorView ORCID ID profile
© The Author(s) 2018
- Received: 30 March 2018
- Accepted: 6 June 2018
- Published: 15 June 2018
Inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo GTP biosynthesis, plays an important role in cell metabolism and proliferation. It has been demonstrated that IMPDH can aggregate into a macrostructure, termed the cytoophidium, in mammalian cells under a variety of conditions. However, the regulation and function of the cytoophidium are still elusive.
In this study, we report that spontaneous filamentation of IMPDH is correlated with rapid cell proliferation. Intracellular IMP accumulation promoted cytoophidium assembly, whereas elevated GTP level triggered disassociation of aggregates. By using IMPDH2 CBS domain mutant cell models, which are unable to form the cytoophidium, we have determined that the cytoophidium is of the utmost importance for maintaining the GTP pool and normal cell proliferation in the condition that higher IMPDH activity is required.
Together, our results suggest a novel mechanism whereby cytoophidium assembly upregulates IMPDH activity and mediates guanine nucleotide homeostasis.
- IMPDH enzyme
- GTP biosynthesis
- Cell proliferation
Purine nucleotides are essential molecules for a variety of cell functions. They not only serve as the building blocks of DNA and RNA, but also participate in cell metabolism as cofactors or energy donors, and are involved in cell signal transduction and cytoskeleton organisation. Imbalance of nucleotide pools may lead to cell cycle arrest, mistakes in nucleic acid synthesis or even cell death. Thus, the precise regulation of nucleotide biosynthesis is crucial for regular cell metabolism .
Purine nucleotides can be synthesized by a salvage pathway or a de novo synthetic pathway. By the former purine free bases will be recycled by hypoxanthine/guanine phosphoribosyl transferase (HGPRT), adenine phosphoribosyl transferase (APRT) or adenosine kinase (ADK), whilst by the latter the purine ring is assembled in serial steps from precursors of carbohydrate and amino acid metabolism.
Inosine monophosphate (IMP) is a common precursor in adenine and guanine nucleotide de novo synthetic pathways. IMP dehydrogenase (IMPDH) catalyses the NAD-dependent conversion of IMP to xanthine monophosphate (XMP), the rate-limiting step of guanine nucleotide synthesis. Because of its pivotal role in nucleotide production, IMPDH inhibitors have been applied in therapies for auto-immune diseases, infectious diseases and cancers. For example, mycophenolic acid (MPA), a metabolite of mycophenolate sodium or mycophenolate mofetil, works as an immunosuppressant and is widely used to prevent rejection upon organ transplantation and in the treatment of some forms of systemic lupus erythematosus (SLE) and vasculitis [2–4]. In addition, ribavirin is used in combination with interferon-α for the treatment of chronic hepatitis C virus infection (HCV), and tiazofurin was once an orphan drug for chronic myelogenous leukemia [5–8].
In mammals, two IMPDH isoforms, IMPDH1 and IMPDH2, are encoded by individual genes. They share 84% identical amino acid sequences and indistinguishable kinetic properties but differ in expression patterns [2, 9–11]. IMPDH2 is the predominant isoform in most tissues, whilst IMPDH1 is generally expressed at a low level except in certain tissues including retina, spleen and in resting peripheral blood mononuclear cells [12–14]. Although the tetramer is a stable state for IMPDH, the formation of IMPDH octamers and even higher order polymers has been shown in recent studies [15–18]. IMPDH contains a catalytic domain and a subdomain consisting of two repeated cystathionine β-synthase (CBS) domains. Despite its dispensable role for catalytic activity in vitro, the CBS domain has been demonstrated as responsible for mediating the allosteric inhibition and polymerisation of IMPDHs [12, 17–20].
The cytoophidium (plural: cytoophidia) is an organelle-like macrostructure comprised of metabolic enzymes [21–23]. The term cytoophidia comes from the Greek for “cellular snakes”, although these structures are also known as Rods and Rings (RR) from its shape [24–26]. In mammalian cells, IMPDH and cytidine triphosphate synthase (CTPS) are two identified components of the cytoophidium [15, 24, 27, 28]. By electron microscopic analysis, it has been shown that the cytoophidium is composed of a huge bundle of protein polymer fibres [17, 29, 30]. Although IMPDH and CTPS are able to form the cytoophidium independently, their colocalisation is frequently observed [24, 31, 32].
Despite the inhibitory effect of CTPS activity from polymerization has been reported in bacterial models, a more recent study shows a converse scenario on purified human CTPS1 [33, 34]. As the mutant CTPS without the ability to polymerize displayed significantly lower catalytic activity in vitro, the function of polymerization for upregulation of CTPS activity has been demonstrated . In contrast, an in vitro study suggests that polymerization of human IMPDH is independent of the regulation of its catalytic activity . However, results from purified proteins could not fully represent the whole picture of the cytoophidium, which is a much larger and probably much more complicated structure than protein polymers. Further investigation is required to learn the role of the cytoophidium in cell metabolism.
In this study, our focus will be on the IMPDH-based cytoophidium. In all mammalian cells tested so far, IMPDH cytoophidia could be induced by inhibitors that impede GTP biosynthesis, and disassembled by guanosine or GTP supplementation [15, 20, 24]. However, the cytoophidium is also found in multiple cell types under drug-free culture conditions [31, 36]. For instance, the natural presence of IMPDH cytoophidia was detected in about 95% of mouse embryonic stem cells (ESCs) . Moreover, IMPDH spontaneously forms cytoophidia in mouse pancreatic islet cells in response to nutrient uptake . Since GTP participates in the regulatory pathway of insulin secretion, the physiological correlativity of the IMPDH cytoophidium has been proposed [31, 37]. Observations to date suggest that IMPDH cytoophidium assembly is a natural biological phenomenon involving purine metabolism, although its regulation and function remain largely unclear.
Herein, we aim to explore the regulation and the fundamental function of the IMPDH cytoophidium. We firstly show that the spontaneous formation of the IMPDH cytoophidium in mouse induced pluripotent stem cells (iPSCs) is correlated with rapid cell proliferation. Secondly, we determine that IMPDH cytoophidium assembly is promoted by its substrate IMP. Finally, by applying the CRISPR/Cas9 genome editing system, we established IMPDH2 CBS domain mutant HeLa cell lines with no cytoophidium-forming capability. With these distinctive model cells, we discovered that formation of the cytoophidium, by IMPDH1 and IMPDH2, is required for producing sufficient amounts of guanine nucleotides to maintain normal cell proliferation when the intracellular IMPDH level is not adequate. Collectively, we propose that formation of the cytoophidium is a novel mechanism to boost IMPDH activity and mediate nucleotide homeostasis.
Cell culture and transfection
HEK 293T cells and HeLa cells (obtained from Culture Collections, Public Health England #93021013) were cultured in DMEM with high glucose (Thermo Fisher Scientific) and supplemented with 10% FBS (Thermo Fisher Scientific), 2 mM l-Glutamine and 1% Gibco® Antibiotic–Antimycotic (Thermo Fisher Scientific). Mouse iPSCs, which were kindly provided by Prof. Paul Fairchild (from Sir Willian Dunn School of Pathology, University of Oxford), were cultured without feeders in a surface coated with 0.1% porcine skin gelatin with a homemade medium: DMEM (Sigma #D6546), 15% FBS batch tested (Gibco #16000-036), 2 mM l-Glutamine, 1% Penicillin/Streptomycin (Gibco), 1% Non-Essential amino acids (Gibco), 0.1% of β-Mercaptoethanol stock solution (obtained by dilution of 70 µl 100% in 20 ml PBS), 1000 units/ml of mLIF (Millipore #ESG1107). Culture medium was replaced every 2 days for mouse iPSCs and pluripotency was monitored by characteristic colony formation. All cells were cultured in a 37 °C humid incubator with 5% CO2. Thymidine (Sigma #T1895), guanosine (Sigma #G6264), allopurinol (MP Biomedicals #0219015001) and MPA (Alfa Aesar #J61905) were dissolved in DMSO (Sigma-Aldrich). DON (Sigma #D2141), ribavirin (Abcam #ab120660), dCTP (Invitrogen #10217016) and GTP (Sigma #G8877) were dissolved in water. All drugs were applied in the concentrations as indicated. For cell transfection with constructs, lipofectamine 3000 reagent (Thermo Fisher Scientific) was used for HEK 293T cells and effectene transfection reagent (QIAGEN) was used for HeLa cells. All transfection procedures were according to instructions provided by manufacturers.
Establishment and characterisation of mutant cell colonies with CRISPR/Cas9
The plasmid pU6-(BbsI)_CBh-Cas9-T2A-mCherry was a gift from Prof. Ralf Kühn (Addgene plasmid # 64324) , was used for generating mutant HeLa cell lines. In brief, the plasmid was digested with restriction enzyme Bpil (Thermo Fisher Scientific) and purified. Subsequently, sgRNA oligonucleotide was inserted into the opened plasmid with NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs). Sequences of sgRNAs for IMPDH1 and IMPDH2 are shown in Additional file 1: Table 1. Two days after transfection, HeLa cells expressing mCherry were sorted and single cells were seeded into 96-well plate. About 2 weeks later, the DNA targeted regions as described in Results for the interested colonies were PCR amplified with primers shown in Additional file 1: Table 1, DNA fragments were cloned into carrier vectors with Gibson Assembly Master Mix (New England Biolabs) and used for DH5α bacterial transformation. Random colonies were picked and the vector extracted was sequenced for characterisation of individual alleles.
For myc-IMPDH1 and myc-IMPDH2 overexpression, the IMPDH1 and IMPDH2 coding sequences were amplified with primers shown in Additional file 1: Table 1 and inserted into pTRE2hyg plasmid (Clontech). For GMPR overexpression, the coding sequence (NCBI Reference Sequence: NM_006877.3) was amplified from HeLa total cDNA (See Real-time q-PCR methods) with primers shown in Additional file 1: Table 1 and inserted into linearized pCMV3-N-OFPSpark plasmid (Sino Biological), together with a DNA fragment containing the P2A sequence, with Gibson Assembly Master Mix (New England Biolabs). Mutant plasmids were generated with QuikChange II Site-Directed Mutagenesis Kit (Agilent) and protocols provided by the manufacturer.
For the concomitant overexpression of fluorescent-tagged IMPDH1 and IMPDH2, plasmids used were pEZ-M32-eCFP-N-IMPDH1 (GeneCopeia #EX-Z3998-M32) and pCMV3-OFPSpark-N-IMPDH2 (Sino Biological #HG14878-ANR).
For the knockdown of IMPDH2 mRNA, a pool of four predesigned siGENOME SMARTpool siRNA IMPDH2 was used in the indicated concentrations (GE Dharmacon #M-004331-02-0010). Sequences are presented in Additional file 1: Table 1. As control, siGENOME Non-Targeting siRNA pool was transfected in the same concentrations as the target (GE Dharmacon #D-001206-13-05). For the transfection of siRNAs, Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific) was used following instructions provided by the manufacturer. siRNA transfection efficiency was monitored with siGLO green transfection indicator (GE Dharmacon) as shown in Additional file 1: Fig. 3d.
For EdU incorporation, 15–20 min before fixation cells were incubated with 20 µM of EdU. After 4% PFA fixation, a Click-iT® azide-based reaction was performed to bind Alexa Fluor 647 molecule to the EdU incorporated to newly synthesized DNA. All procedures followed manufacturer protocol (Thermo Fisher Scientific).
Nucleotide analysis by UPLC
Quantification of intracellular nucleotides was performed as described previously [31, 39]. In brief, 7 × 106 cells were lysed in 80% methanol. After centrifugation at 13,000×g for 10 min, the supernatants were collected and dried. Pellets were resuspended in water and analyzed using Acquity Ultra Performance Liquid Chromatography (UPLC, Waters) interfaced with a PDA photodiode array (Waters).
IMPDH enzyme activity measurement
IMPDH enzyme activity was measured in total cell extract for the given cell lines with an assay that is based on the reduction of INT in a NADH-coupled reaction to INT-formazan which exhibits an absorption maximum at 492 nm and allows for sensitive measurement of IMPDH activity in a plate reader. The assay was performed following the manufacturer recommendations (BMR Service #E-119; School of Medicine and Biomedical Sciences, State University of New York at Buffalo).
Immunofluorescence was performed as previously described . Primary antibodies used: Rabbit Polyclonal anti-IMPDH2 antibody (ProteinTech, 12948-1-AP); Mouse monoclonal anti-IMPDH1 antibody (Abcam, ab55297); Mouse monoclonal anti-c-Myc antibody (Santa Cruz Biotech, sc-40). Secondary antibodies used: DyLight 488-Conjugated or Cy™3-Conjugated or DyLight 649-Conjugated Donkey Polyclonal anti-Mouse IgG (Jackson ImmunoResearch #715-165-151; #715-485-151; #715-495-151). Cy™3-Conjugated Donkey Polyclonal anti-Rabbit IgG (Jackson ImmunoResearch #711-165-152); Alexa Fluor® 488-Conjugated or Alexa Fluor® 647-Conjugated Donkey Polyclonal anti-Rabbit IgG (Invitrogen Mol Probes #A-21206; #A-31573). After the immunofluorescence probing, cells were analysed and images captured with a Leica TCS SP5 Confocal microscope.
After the indicated treatment, cells were suspended with trypsin, washed once with PBS and lysed with RIPA buffer added of Protease inhibitor Cocktail (Thermo Fisher Scientific). Further homogenization was obtained by submitting the samples to five medium intensity cycles of sonication with 30 s each cycle. Cell extract was immediately stored in − 80 °C. Protein quantitation was obtained with BCA Protein Assay Kit (Thermo Fisher Scientific). Samples were submitted to denaturation in 95 °C for 10 min in the presence of Laemmli SDS sample buffer (Alfa Aesar). About 10 µg of protein was loaded in each well of 15/wells NuPAGE™ Bis–Tris gels, run with XCell SureLock™ Mini-Cell Electrophoresis System and transfer to nitrocellulose membrane with XCell II™ Blot Module (Thermo Fisher Scientific). After 2 h blocking with TBS + 5% milk, primary antibodies diluted in TBS + 5% milk were incubated overnight for 1 or 2 nights at 4 °C. After three times washing of the membrane with TBS, secondary antibodies were incubated overnight for 1 night in the same conditions. Antibody labelling was revealed with SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and visualized in a G:BOX Chemi XT4 machine (Syngene).
Primary antibodies used: Rabbit Polyclonal anti-IMPDH2 (ProteinTech #12948-1-AP); Mouse monoclonal anti-IMPDH1 (Abcam #ab55297); HRP-Conjugated Mouse monoclonal anti-ACTB or anti-GAPDH (ProteinTech #HRP-60008; #HRP-60004). Secondary antibodies used: HRP-Conjugated Donkey Polyclonal anti-Mouse IgG or anti-Rabbit IgG (Jackson ImmunoResearch #715-035-150; #711-035-152).
After the appropriate transfection or treatment as indicated in Results, the cells were suspended with trypsin, centrifuged, and the RNA was extracted using miRNeasy Mini Kit (Qiagen #217004;) according to the manufacturer’s protocol. The amount of RNA obtained was quantitated by NanoDrop 2000c. RNA samples were immediately stored in a − 80° freezer. Reverse Transcriptase (RT) conversion of RNA to cDNA was made with Maxima First Strand cDNA Synthesis Kit with dsDNase (Thermo Fisher Scientific #K1671) according to the manufacturer’s protocol. The cDNA was stored in a − 20° freezer until the qPCR reaction. Quantitative PCR (qPCR) reaction was performed using 7500 Fast Real Time PCR System (Applied Biosystems), with SYBR Green ReadyMix (Sigma #S4438) as amplification indicator according to manufacturer protocol. Standard 60° Tm annealing temperature and 40 amplification cycles was used for all primer pairs. The quality of reaction was evaluated by Melt curve. Each sample was run in duplicate or triplicate. Target Ct genes were analysed by comparison with housekeeping references through ΔΔCt method. GAPDH was used as housekeeping reference. Primers used are presented in Additional file 1: Table 1.
Image analysis and statistical comparisons
Images captured by the microscope were analysed using ImageJ 1.51 software. Proportion of cells presenting the given characteristic, such as cytoophidium presence or EdU labelling, was obtained by quantification of at least two randomly captured images (> 200 cells) in each of at least two independent experiments, unless stated otherwise. All western blot experiments were repeated at least twice with independent samples, and the intensity of the band was quantified using the Surface Plot tool in ImageJ software, normalized for the housekeeping reference. Average size of cytoophidium was estimated with the Analyse Particles tool in ImageJ, with a threshold value arbitrary settle to 50. The classification as high or low fluorescence intensity for cells expressing OFP (for example OFP-P2A-GMPR_wt) was obtained using ImageJ with a threshold settle at 50.
The data is presented as Mean plus error bars indicating Standard Deviation (SD) or Standard Error of the Mean (SEM) as described in figure legends. For the statistical comparison of quantitative and semi-quantitative parameters of different time-points of the same treatment, paired Student’s t test was used. For the comparison of different groups and/or different treatments, unpaired Student’s t-test was used. P ≤ 0.05 was considered statistically significant. All analyses were done with Microsoft Office Excel® or GraphPad Prism 5.0 software.
IMPDH-based cytoophidium assembly in iPSCs responds to GTP levels and proliferation arrest
IMPDH cytoophidia can be induced both in vivo and in vitro under various conditions that interfere with de novo GTP synthesis, including treatment with IMPDH inhibitors, such as azathioprine, MPA and ribavirin, and others, including methotrexate, acyclovir, decoyinine, deazauridine (DAU) and 6-diazo-5-oxo-L-norleucine (DON) [15, 20, 24, 31, 40]. However, IMPDH cytoophidia were also observed in certain cell types without such drug stimulation [24, 31, 36]. To further explore the correlation between cytoophidium formation, purine metabolism and cell proliferation, we attempted to analyse the cytoophidium in a cell model with a high amount of IMPDH cytoophidia under normal culture conditions.
IMP promotes IMPDH filamentation
We find that the high consumption of guanine nucleotides may be related with the presence of cytoophidium in iPSCs, evidenced by the rapid proliferation of these cells. We then suspect that, to support the de novo synthesis of guanine nucleotides, the substrate IMP supply would also be upregulated. This prompts us to examine whether IMP accumulation could promote IMPDH cytoophidium formation. Our previous study shows that the treatment with DAU leads to the temporal presence of IMPDH cytoophidia in HEK 293T cells with an elevated GTP level . We suspected that is a consequence of IMP accumulation due to the inhibition of pyrimidine synthesis by DAU.
In mammalian cells, apart from the de novo synthetic pathway, IMP could also be converted from hypoxanthine and GMP by HGPRT and GMPR, respectively (Fig. 2a). First, we treated HEK 293T cells with allopurinol, which impedes hypoxanthine degradation by inhibiting xanthine oxidase, thereby enhances reutilization of hypoxanthine and xanthine to generate IMP [41, 42]. After 1 h of treatment, the percentage of cells with IMPDH cytoophidia significantly increased in a dose dependent manner (Fig. 2b, c). Additionally, we also aimed to increase the IMP level by activating the conversion of GMP to IMP, by which intracellular IMP should increase without an elevation in GTP level. To this end we constructed an OFP-P2A-GMPR plasmid, with which the GMPR expression level in transfected cells could be monitored by fluorescence intensity. Normally, IMPDH cytoophidia are detected in < 5% of HeLa cells. Surprisingly, when HeLa cells were transfected with the OFP-P2A-GMPR plasmid, the percentage of cells with cytoophidia dramatically surged to 84 ± 3.7% for cells with high fluorescence intensity. Even the cell population with lower GMPR expression level contained 38 ± 11.5% of cells with cytoophidia (Fig. 2d, f). To exclude possibilities other than the increased GMPR activity to induce cytoophidium formation, we further carried out site-directed mutagenesis to generate plasmids encoding two catalytic dead GMPR mutants, C186A and T188A (PDB 2BWG) [43, 44]. After transfection, the cytoophidia were no longer observed, indicating that filamentation of IMPDH was triggered by increased GMPR activity (Fig. 2e, f). Meanwhile, GMPR overexpression does not affect proliferation rate or IMPDH2 protein levels, implying the intracellular GTP level was not significantly affected by GMPR (Additional file 1: Fig. 2). These findings indicate that IMP accumulation promotes IMPDH cytoophidium formation.
Knockdown of IMPDH2 in HeLa cells promotes cytoophidium assembly but does not affect proliferation rate
Mutation in CBS domain of IMPDH2 impairs cytoophidium assembly
It has been suggested that the CBS domain modulates IMPDH polymerisation. Multiple point mutations on human IMPDH1 have been identified associated with the retinopathy adRP10. Among them, R224P and D226 N mutations can alter IMPDH1 filament-forming properties in human cells . In addition, purified human IMPDH1 D226 N protein tends to comprise large aggregates, which are formed by numerous intertwined IMPDH1 fibres in vitro . However, none of these adRP10-related point mutations has been observed in IMPDH2. Perhaps because IMPDH2 is the predominant isoform in most tissues, therefore any abnormality may lead to severe defects, even embryonic lethality [46, 47]. We wondered whether such mutations on IMPDH2 would result in the same consequences as on IMPDH1 regarding filament-forming properties.
We firstly generated R224P, D226 N and R231P myc-IMPDH1 mutants. All of them formed irreversible cytoophidia in transfected HEK 293T cells when treated with guanosine (Additional file 1: Fig. 4a, c). Next, we examined the same mutations on myc-IMPDH2. Similar to the IMPDH1 mutants, D226 N and R231P myc-IMPDH2 mutants formed irreversible cytoophidia that could not be disassembled by the given guanosine treatment. Surprisingly, however, the myc-IMPDH2 R224P mutant abolished the cytoophidia in transfected cells under the condition of supplementation with MPA (Additional file 1: Fig. 4b, c). These results indicate the distinct features of the IMPDH1 and IMPDH2 CBS domains, and also suggest that it is possible to prevent IMPDH cytoophidium formation by introducing mutations in the IMPDH2 CBS domain.
Endogenous mutations on CBS domain prevent cytoophidium assembly
In order to determine if forming the cytoophidium is necessary for facilitating GTP production in certain conditions, we sought to establish a cell model with no capability to form IMPDH cytoophidia. To achieve this, we applied CRISPR/Cas9 genome editing technique to induce mutagenesis in the CBS domain of endogenous IMPDH2 of HeLa cells with a sgRNA targeting exon 7, which corresponds to amino acid 224–230. Out of over 150 single-cell clones, two colonies exhibited the ‘no-cytoophidium’ phenotype under induction with ribavirin, MPA and DON (Fig. 4a). With sequencing analysis, we confirmed that one colony (mut-IMPDH2 Col_5) had a deletion of six residues from 227 to 232 in one allele and no mutation in the other (Fig. 4b). The other colony (mut-IMPDH2 Col_32) had a deletion of eight residues (Δ225–232) in one allele, a deletion of six residues (Δ227–232) in another allele, and at least one extra allele of wild-type IMPDH2 (Fig. 4b). Under normal culture conditions, no defects in cell proliferation rate and IMPDH2 levels have been observed in both colonies (Fig. 5a, b).
Although it has been reported previously that truncation of the entire CBS domains has no impact on IMPDH activity in vitro, point mutations is still possible to change certain properties of the enzyme, including catalytic activity [18, 19]. To determine whether the deletions in CBS domain could affect IMPDH2 activity, we conducted an in vitro IMPDH activity analysis for cell lysates of wild type, mut-IMPDH2 Col_5 and mut-IMPDH2 Col_32 cells. While mut-IMPDH2 Col_5 showed 30% lower activity, the IMPDH activity of mut-IMPDH2 Col_32 was similar to that of the wild-type cells, within error (Fig. 5c). All cell lines showed indistinguishable IMPDH2 level, while mut-IMPDH2 Col_5 cells had a lower amount of IMPDH1 and mut-IMPDH2 Col_32 cells expressed more IMPDH1 than wild-type cells (Fig. 5b). Such differences in in vitro catalytic activity assay may be attributed to the variances of their IMPDH1 level. Since mut-IMPDH2 Col_32 cells, which have similar expression level of IMPDHs as wild-type cells, showed comparable activity with wild-type cells, we suggest that the deletions in CBS domain do not affect IMPDH2 activity.
To ensure that the ‘no-cytoophidium phenotype’ in mut-IMPDH2 Col_5 and mut-IMPDH2 Col_32 cells is truly the result of the deletion of six residues (Δ227–232) in part of IMPDH2 proteins, we also overexpressed the mutant IMPDH2 in wild type HeLa cells and observed the absence of cytoophidium assembly under ribavirin treatment (Additional file 1: Fig. 5).
Cytoophidium assembly is important for keeping normal proliferation rate of HeLa cells when IMPDH2 expression is suppressed
Our results show that under IMPDH2 knockdown, cytoophidium assembles and the proliferation rated of the cells was not affected. We ask if the same would happen with the ‘no-cytoophidium phenotype’ cell lines. Thus, transfection of IMPDH2 siRNAs in mutant HeLa cell lines was carried and nucleotide levels and their proliferation rates were analysed. Interestingly, 48 h after IMPDH2 knockdown, with the lack of cytoophidia, the percentage of EdU-positive cells in mut-IMPDH2 Col_5 and mut-IMPDH2 Col_32 declined to 66 ± 4.4 and 57 ± 2.7% of the original proportion (normalized to 100% for each cell line), whereas the proliferation rate of wild-type cells was not affected under the same condition (Fig. 5a, d). Notably, we observed small cytoophidia in 9.7 ± 1.7% of IMPDH2 siRNA-transfected mut-IMPDH2 Col_32 cells (arrows in Fig. 5a). We speculated that these cytoophidia observed under the IMPDH2 knockdown condition could be formed mainly by IMPDH1 and wild-type IMPDH2 when the amount of mutant IMPDH2 protein, which interferes with filamentation, was no longer enough for preventing cytoophidium assembly (Fig. 5a).
To test whether the decrease in proliferation rate, caused by IMPDH2 knockdown, in mut-IMPDH2 Col_5 and mut-IMPDH2 Col_32 cells is a consequence of an inadequate GTP pool, we analysed nucleotide levels in given conditions with UPLC. When IMPDH2 level decreased, the GTP/ATP ratio of wild-type HeLa cells slightly declined from 0.187 to 0.161 (ΔGTP/ATP = 0.026). Moreover, the GTP/ATP ratio of mut-IMPDH2 Col_5 and mut-IMPDH2 Col_32 cells reduced 0.843 and 0.760, respectively, which are 3.22 and 2.9-fold of ΔGTP/ATP of wild-type cells (Fig. 5e and Additional file 1: Fig. 6a). Meanwhile, the CTP/ATP and UTP/ATP levels of all three cells lines were only slightly affected (Additional file 1: Fig. 6b). Next, we supplemented guanosine or GTP in the medium following IMPDH2 knockdown in order to compensate the defect of GTP production. With treatments with guanosine or GTP, proliferation rates of two mutant colonies restored to a normal level (Fig. 5d).
We then transfected IMPDH1-Ko cells with IMPDH2 siRNAs at low (0.1 nM) and high (100 nM) concentration and analysed the proliferation rate. When cells were transfected with 0.1 nM siRNAs, cytoophidia were observed in 50.9 ± 21.7% of cells and no defect in cell proliferation was seen (Fig. 6c, d). However, when cells were transfected with the high dose of siRNAs, only 18.3 ± 4.9% of cells exhibited cytoophidia and cell proliferation significantly decreased to 55 ± 3.9% of the original level (Fig. 6c, d). Notably, since there was no IMPDH1 present in the cells, these cytoophidia were composed of remaining IMPDH2 (Fig. 6f). Moreover, a clear correlation between cells with cytoophidia and proliferating cells (EdU positive) was found (arrows in Fig. 6c). While 51 ± 7.8% of cytoophidium expressing cells were labelled by EdU, only 9 ± 4.2% of cells without cytoophidia were EdU positive (Fig. 6e). Taken together, our results suggest that the cytoophidium structure is of the utmost importance for upregulating IMPDH activity and maintaining the intracellular GTP level during certain circumstances, such as decreased IMPDH protein level or an increase of GTP consumption, thereby coordinates the supply and demand of guanine nucleotides.
IMPDH plays a key role in purine nucleotide biosynthesis and hence contributes to controlling cell metabolism and proliferation. Therefore, IMPDH has drawn attention as a promising target in various clinical applications. For example, IMPDH inhibitors, such as MPA and ribavirin, are widely used as an immunosuppressant and for treatment of HCV infection, respectively. These drugs, and other conditions that disturb de novo GTP production, are known to induce massive cytoophidia formation in vitro or in vivo . As a result, the IMPDH cytoophidium has been considered as a consequence of IMPDH inhibition or GTP insufficiency [15, 20, 24, 48]. However, our previous report suggests that the assembly of cytoophidia reflects upregulation of GTP synthesis . In the current study, we provide multiple lines of evidence that IMP promotes IMPDH filamentation. Since it has been shown that the IMP binding affinity of IMPDH could be greatly reduced by the conformational change due to GDP/GTP binding at the CBS domain , we propose that the formation of the IMPDH cytoophidium is positively correlated with the ratio of intracellular IMP to guanine nucleotides.
In mouse iPSCs, active glycolysis and de novo nucleotide biosynthesis are essential features for supporting their rapid proliferation, although it is not necessarily specific to a pluripotent state. The balance between the high levels of GTP production and consumption is suggested as the reason for the presence of IMPDH cytoophidia in ~ 80% of iPSCs. Any treatment that interrupts this balance could perturb IMPDH aggregation. For instance, cell cycle arrest and GTP supplementation, which may result in GTP accumulation, significantly decreased the proportion of cells with cytoophidia. In contrast, both treatments with allopurinol or overexpression of GMPR may facilitate the generation of IMP through salvage and recycling pathways and thereby induce cytoophidium formation in HEK 293T cells and HeLa cells.
On the other hand, it has been demonstrated that the CBS domain of IMPDH is dispensable for enzyme activity in vitro, but participates in the regulation of nucleotide pools and also IMPDH filamentation [18–20]. Several IMPDH1 mutations in CBS domains are known to be related to retinopathy adRP10 . Among them, the R224P and D226 N mutants were shown to perturb IMPDH clustering in cells . Herein, we found that another adRP10-related IMPDH1 mutant, R231P, also enforces IMPDH to assemble irreversible cytoophidia. Interestingly, despite these mutant residues being conserved in IMPDH2, we observed a different effect from IMPDH2 R224P. Instead of assembling into the cytoophidium, IMPDH2 R224P prevented clustering of both isoforms. These findings support the notion that the CBS domain plays a key role in mediating cytoophidium assembly. A natural product sanglifehrin A (SFA), has been shown to form a complex with protein cyclophilin A (PPIA) inside human cells . The PPIA-SFA complex is able to bind with IMPDH2, but not IMPDH1, at the CBS domain and thereby suppress proliferation of lymphocytes. Although the mechanism results in cell growth inhibition and whether the binding of PPIA-SFA would disturb IMPDH filamentation is currently unclear, this suggests that it is possible to modulate IMPDH filamentation with molecules targeting the CBS domain.
The octameric state of IMPDH has been suggested to play an important role in allosteric regulation and formation of IMPDH fibres [17, 18, 51]. Structures of two types of octamers of human IMPDH1 have been revealed and it is suggested that these two octameric architectures could pile up to form protein fibres . These IMPDH fibres could further associate together forming a higher order structure, which is very likely the cytoophidium in cells [17, 30].
Recently, a publication by Anthony et al.  shows that the IMPDH cytoophidium accommodates both catalytically active and inactive conformations of the enzyme. They also identified three additional point mutations in human IMPDH2 that interfere with cytoophidium assembly, while S275L overexpression results in permanent filament formation, Y12A and R356A disrupt filamentation, even in the presence of MPA. No difference in catalytic activity was detected in all three mutant IMPDH2 proteins in vitro when compared with wild-type IMPDH2. Similarly, HEK293 cells overexpressing S275L mutant and S275L/Y12A double mutant IMPDH2 proteins exhibited indistinguishable guanine nucleotide biosynthetic rate. However, overexpression of IMPDH may not be the best way to study such effects on catalytic activity as the GTP level might be always above the normal level, which could bring negative feedback to the biosynthetic pathway and suppress IMPDH activity .
Herein, we generated mutant HeLa cell lines having a deletion in the CBS domain of endogenous IMPDH2 and characterised these mutant cells as being unable to form the cytoophidium. Although no growth defect was found under normal conditions, these mutant cells could not sustain the normal GTP pool and cell proliferation rate when the expression of IMPDH2 was suppressed. Despite the transcriptional function of IMPDH has been demonstrated , our data suggest that assembly of the IMPDH cytoophidium is correlated with its catalytic function. Since a growth defect in mutant cells was only seen when IMPDH2 was knocked down, the IMPDH cytoophidium seems not to be essential for IMPDH being active but important for another aspect of enzyme regulation. Polymerization of active acetyl-CoA carboxylase has been described more than 30 years ago . More recently, the substrates promoted polymerization of human CTPS1, which is not essential for CTPS1 being active, has been revealed as to increase its catalytic activity . It is suggested that an active conformation of human CTPS1, which may facilitate ammonia transfer between two active sites, is stabilized in the filaments. This may keep CTPS in a primed state of maximal activity under certain conditions in which higher CTP production is required for the cell . We propose that formation of the IMPDH cytoophidium have a similar purpose to facilitate the catalytic reaction of IMPDH by putting the enzyme into a hyperactive state in response to an elevated ratio of IMP to guanine nucleotides. Indeed, the model of IMPDH polymer demonstrated by prior study implies the polymer may coordinate IMPDH octamer conformational changes, although further analysis is still needed to reveal how that affects the catalytic activity of IMPDH .
In summary, we show that the formation of the IMPDH cytoophidium is controlled by the levels of IMP and GTP, by which the production of and demand for guanine nucleotides can be exquisitely coordinated. Moreover, cytoophidium assembly in mouse iPSCs correlates with the high proliferation rate observed in those cells. Cytoophidium assembly may be involved in upregulation of the whole system of de novo purine nucleotide biosynthesis, which these cells heavily depend on. In addition, the assembly of the cytoophidium may induce a hyperactive state in both IMPDH1 and IMPDH2 under specific cell metabolic conditions, as for example when the amount of IMPDH2 was artificially decreased. Taken together, our findings shed light on the fundamental regulation and function of the IMPDH cytoophidium in mammalian cells, providing new insight into the control of IMPDH activity and guanine nucleotide homeostasis. Considering the important role of IMPDH in clinical applications, our results propose a new perspective for drug development in the future. Further studies are needed to elucidate how filamentation changes the IMPDH protein folding structure and how such alterations affect enzyme activity by, for example, facilitating the binding of IMPDH to its substrate IMP.
GDK and CCC design the experiments, perform experiments and wrote the manuscript. MP, LYC, WCL and LMP perform experiments and analysed the data. LECA, LYS and JLL design the study, analysed data and revised the manuscript. All authors read and approved the final manuscript.
We acknowledge Prof. Paul Fairchild (from Sir Willian Dunn School of Pathology, University of Oxford) for the donation of mouse induced pluripotent stem cells. We also acknowledge the team in the Flow Cytometry Facility from the Sir Willian Dunn School of Pathology, University of Oxford, for the assistance with single-cell sorting.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its additional files].
Consent for publication
Ethics approval and consent to participate
This work was supported by Brazilian government research funding agency CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) through the scholarship #232711/2014-3 Granted to GDK. This work was supported by Ministry of Science and Technology, Taiwan, ROC #104-2313-B-002-035-MY3 Granted to LYS and #106-2917-I-002-043 Granted to CCC. This work was supported by the Medical Research Council UK. The funders had no role in study designs, data collection and interpretation, or the decision to submit the work for publication.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rudolph FB. The biochemistry and physiology of nucleotides. J Nutr. 1994;124(1 Suppl):124S–7S.View ArticlePubMedGoogle Scholar
- Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268(36):27286–90.PubMedGoogle Scholar
- Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006;8(6):R182.View ArticlePubMedPubMed CentralGoogle Scholar
- Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation. 2009;87(6):785–94.View ArticlePubMedGoogle Scholar
- Franchetti P, Grifantini M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem. 1999;6(7):599–614.PubMedGoogle Scholar
- Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310(2):333–42.View ArticlePubMedGoogle Scholar
- Pankiewicz KW, Patterson SE, Black PL, Jayaram HN, Risal D, Goldstein BM, Stuyver LJ, Schinazi RF. Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)—the major therapeutic target. Curr Med Chem. 2004;11(7):887–900.View ArticlePubMedGoogle Scholar
- Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Collart FR, Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem. 1988;263(30):15769–72.PubMedGoogle Scholar
- Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265(9):5292–5.PubMedGoogle Scholar
- Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995;49(9):1323–9.View ArticlePubMedGoogle Scholar
- Senda M, Natsumeda Y. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.184.108.40.206). Life Sci. 1994;54(24):1917–26.View ArticlePubMedGoogle Scholar
- Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, Germann UA. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol. 2004;67(4):767–76.View ArticlePubMedGoogle Scholar
- Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellicy CJ, Gire AI, Hughbanks-Wheaton D, Birch DG, Lewis RA, Heckenlively JR, Daiger SP. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006;47(1):34–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem. 2006;281(1):206–12.View ArticlePubMedGoogle Scholar
- Gilbert HJ, Lowe CR, Drabble WT. Inosine 5′-monophosphate dehydrogenase of Escherichia coli. Purification by affinity chromatography, subunit structure and inhibition by guanosine 5′-monophosphate. Biochem J. 1979;183(3):481–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Labesse G, Alexandre T, Vaupre L, Salard-Arnaud I, Him JL, Raynal B, Bron P, Munier-Lehmann H. MgATP regulates allostery and fiber formation in IMPDHs. Structure. 2013;21(6):975–85.View ArticlePubMedGoogle Scholar
- Buey RM, Ledesma-Amaro R, Velazquez-Campoy A, Balsera M, Chagoyen M, de Pereda JM, Revuelta JL. Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases. Nat Commun. 2015;6:8923.View ArticlePubMedPubMed CentralGoogle Scholar
- Pimkin M, Markham GD. The CBS subdomain of inosine 5′-monophosphate dehydrogenase regulates purine nucleotide turnover. Mol Microbiol. 2008;68(2):342–59.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomas EC, Gunter JH, Webster JA, Schieber NL, Oorschot V, Parton RG, Whitehead JP. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms. PLoS ONE. 2012;7(12):e51096.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu JL. Intracellular compartmentation of CTP synthase in Drosophila. J Genet Genomics. 2010;37(5):281–96.View ArticlePubMedGoogle Scholar
- Liu JL. The enigmatic cytoophidium: compartmentation of CTP synthase via filament formation. BioEssays. 2011;33(3):159–64.View ArticlePubMedGoogle Scholar
- Liu JL. The cytoophidium and its kind: filamentation and compartmentation of metabolic enzymes. Annu Rev Cell Dev Biol. 2016;32:349–72.View ArticlePubMedGoogle Scholar
- Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, Chan JY, Yao B, Tamayo S, Covini G, von Muhlen CA, Chan EK. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS ONE. 2011;6(12):e29690.View ArticlePubMedPubMed CentralGoogle Scholar
- Calise SJ, Purich DL, Nguyen T, Saleem DA, Krueger C, Yin JD, Chan EK. ‘Rod and ring’ formation from IMP dehydrogenase is regulated through the one-carbon metabolic pathway. J Cell Sci. 2016;129(15):3042–52.View ArticlePubMedGoogle Scholar
- Keppeke GD, Calise SJ, Chan EK, Andrade LE. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-alpha/ribavirin therapy. World J Gastroenterol. 2016;22(6):1966–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen K, Zhang J, Tastan OY, Deussen ZA, Siswick MY, Liu JL. Glutamine analogs promote cytoophidium assembly in human and Drosophila cells. J Genet Genomics. 2011;38(9):391–402.View ArticlePubMedGoogle Scholar
- Gou KM, Chang CC, Shen QJ, Sung LY, Liu JL. CTP synthase forms cytoophidia in the cytoplasm and nucleus. Exp Cell Res. 2014;323(1):242–53.View ArticlePubMedGoogle Scholar
- Ingerson-Mahar M, Briegel A, Werner JN, Jensen GJ, Gitai Z. The metabolic enzyme CTP synthase forms cytoskeletal filaments. Nat Cell Biol. 2010;12(8):739–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Juda P, Smigova J, Kovacik L, Bartova E, Raska I. Ultrastructure of cytoplasmic and nuclear inosine-5′-monophosphate dehydrogenase 2 “rods and rings” inclusions. J Histochem Cytochem. 2014;62(10):739–50.View ArticlePubMedGoogle Scholar
- Chang CC, Lin WC, Pai LM, Lee HS, Wu SC, Ding ST, Liu JL, Sung LY. Cytoophidium assembly reflects upregulation of IMPDH activity. J Cell Sci. 2015;128(19):3550–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Keppeke GD, Calise SJ, Chan EK, Andrade LE. Assembly of IMPDH2-based, CTPS-based, and mixed rod/ring structures is dependent on cell type and conditions of induction. J Genet Genomics. 2015;42(6):287–99.View ArticlePubMedGoogle Scholar
- Lynch EM, Hicks DR, Shepherd M, Endrizzi JA, Maker A, Hansen JM, Barry RM, Gitai Z, Baldwin EP, Kollman JM. Human CTP synthase filament structure reveals the active enzyme conformation. Nat Struct Mol Biol. 2017;24(6):507–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Barry RM, Bitbol AF, Lorestani A, Charles EJ, Habrian CH, Hansen JM, Li HJ, Baldwin EP, Wingreen NS, Kollman JM, Gitai Z. Large-scale filament formation inhibits the activity of CTP synthetase. Elife. 2014;3:e03638.PubMedPubMed CentralView ArticleGoogle Scholar
- Anthony SA, Burrell AL, Johnson MC, Duong-Ly KC, Kuo YM, Simonet JC, Michener P, Andrews A, Kollman JM, Peterson JR. Reconstituted IMPDH polymers accommodate both catalytically active and inactive conformations. Mol Biol Cell. 2017;28:2600–8.View ArticlePubMed CentralGoogle Scholar
- Carcamo WC, Calise SJ, von Muhlen CA, Satoh M, Chan EK. Molecular cell biology and immunobiology of mammalian rod/ring structures. Int Rev Cell Mol Biol. 2014;308:35–74.View ArticlePubMedGoogle Scholar
- Gooding JR, Jensen MV, Dai X, Wenner BR, Lu D, Arumugam R, Ferdaoussi M, MacDonald PE, Newgard CB. Adenylosuccinate Is an Insulin secretagogue derived from glucose-induced purine metabolism. Cell Rep. 2015;13(1):157–67.View ArticlePubMedPubMed CentralGoogle Scholar
- Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kuhn R. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015;33(5):543–8.View ArticlePubMedGoogle Scholar
- Aughey GN, Grice SJ, Shen QJ, Xu Y, Chang CC, Azzam G, Wang PY, Freeman-Mills L, Pai LM, Sung LY, Yan J, Liu JL. Nucleotide synthesis is regulated by cytoophidium formation during neurodevelopment and adaptive metabolism. Biol Open. 2014;3(11):1045–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Keppeke GD, Prado MS, Nunes E, Perazzio SF, Rodrigues SH, Ferraz ML, Chan EK, Andrade LE. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies. Clin Immunol. 2016;173:149–56.View ArticlePubMedGoogle Scholar
- Ogasawara M, Seino T, Hadano S, Ito A, Goto H, Itakura M. Persistent production of hypoxanthine in rat skeletal muscle causes prolonged hyperuricemia after an enhaustice exercise. In: Mikanagi K, Nishioka K, Kelley W, editors. Purine and pyrimidine metabolism in man VI. Advances in experimental medicine and biology. Boston: Springer; 1989. p. 369–74.View ArticleGoogle Scholar
- Hitchings GH. Pharmacology of allopurinol. Arthritis Rheum. 1975;18(6 Suppl):863–70.View ArticlePubMedGoogle Scholar
- Li J, Wei Z, Zheng M, Gu X, Deng Y, Qiu R, Chen F, Ji C, Gong W, Xie Y, Mao Y. Crystal structure of human guanosine monophosphate reductase 2 (GMPR2) in complex with GMP. J Mol Biol. 2006;355(5):980–8.View ArticlePubMedGoogle Scholar
- Patton GC, Stenmark P, Gollapalli DR, Sevastik R, Kursula P, Flodin S, Schuler H, Swales CT, Eklund H, Himo F, Nordlund P, Hedstrom L. Cofactor mobility determines reaction outcome in the IMPDH and GMPR (beta-alpha)8 barrel enzymes. Nat Chem Biol. 2011;7(12):950–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, Morrone S, Frati L, Agliano AM, Giacomello A. Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer. 2004;108(6):812–7.View ArticlePubMedGoogle Scholar
- Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, Mitchell BS. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest. 2000;106(4):599–606.View ArticlePubMedPubMed CentralGoogle Scholar
- Gu JJ, Tolin AK, Jain J, Huang H, Santiago L, Mitchell BS. Targeted disruption of the inosine 5′-monophosphate dehydrogenase type I gene in mice. Mol Cell Biol. 2003;23(18):6702–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Calise SJ, Carcamo WC, Krueger C, Yin JD, Purich DL, Chan EK. Glutamine deprivation initiates reversible assembly of mammalian rods and rings. Cell Mol Life Sci. 2014;71(15):2963–73.View ArticlePubMedGoogle Scholar
- McGrew DA, Hedstrom L. Towards a pathological mechanism for IMPDH1-linked retinitis pigmentosa. Adv Exp Med Biol. 2012;723:539–45.View ArticlePubMedGoogle Scholar
- Pua KH, Stiles DT, Sowa ME, Verdine GL. IMPDH2 is an intracellular target of the Cyclophilin A and Sanglifehrin A complex. Cell Rep. 2017;18(2):432–42.View ArticlePubMedGoogle Scholar
- Buey RM, Fernandez-Justel D, Marcos-Alcalde I, Winter G, Gomez-Puertas P, de Pereda JM, Luis Revuelta J. A nucleotide-controlled conformational switch modulates the activity of eukaryotic IMP dehydrogenases. Sci Rep. 2017;7(1):2648.View ArticlePubMedPubMed CentralGoogle Scholar
- Kozhevnikova EN, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WF, Moshkin YM, Verrijzer CP. Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell. 2012;47(1):133–9.View ArticlePubMedGoogle Scholar
- Beaty NB, Lane MD. The polymerization of acetyl-CoA carboxylase. J Biol Chem. 1983;258(21):13051–5.PubMedGoogle Scholar